Eligible* commercially insured patients may pay as little as $0 out of pocket.
*See Terms & Conditions.
For ELZONRIS claims reimbursement or for a manual rebate for ORSERDU, complete the Claim Submission Form.
ORSERDU (elacestrant), 345 mg tablets, is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after endocrine therapy.
Your healthcare provider will perform a test to make sure that ORSERDU is right for you. It is not known if ORSERDU is safe and effective in children.
ORSERDU may cause serious side effects, including:
Before taking ORSERDU, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. ORSERDU and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
The most common side effects of ORSERDU include:
Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with ORSERDU, if you develop certain side effects.
ORSERDU may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects of ORSERDU. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.
ELZONRIS can cause serious side effects, including:
Your healthcare provider will check your weight and test your blood before you receive each dose of ELZONRIS and as needed during treatment.
Your healthcare provider will periodically test your blood while you are on ELZONRIS to check for liver damage.
Contact your healthcare provider immediately if you have any of these symptoms.
Getting medical treatment right away may help keep these problems from becoming more serious.
If you have any side effects during treatment with ELZONRIS, your healthcare provider may hold your treatment for a period of time or completely stop your treatment with ELZONRIS.
The most common side effects of ELZONRIS include CLS, nausea, feeling tired (fatigue), swelling in your legs or feet, fever, and weight gain.
These are not all of the possible side effects of ELZONRIS. If any new side effects start or an existing one gets worse, contact your healthcare provider immediately. For more information, talk to your treatment team.
Be sure to tell your treatment team about:
You can report any side effects to Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information, including Boxed WARNING, for ELZONRIS to learn more.
The risk information provided here is not comprehensive. To learn more, talk about ELZONRIS (tagraxofusp-erzs) with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at elzonris.com.
ORSERDU (elacestrant), 345 mg tablets, is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after endocrine therapy.
Your healthcare provider will perform a test to make sure that ORSERDU is right for you. It is not known if ORSERDU is safe and effective in children.
ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.
ELZONRIS can cause serious side effects, including: